NUCC-0226272

Cat. No.:	HY-157844
CAS No.:	3004503-12-9
Molecular Formula:	$C_{67}H_{91}N_9O_8S$
Molecular Weight:	1182.56
Target:	PROTACs; Histone Methyltransferase
Pathway:	PROTAC; Epigenetics
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



BIOLOGICAL ACTIVITY

Description	NUCC-0226272 is a potent PROTAC that targets EZH2 for degradation. NUCC-0226272 has anti-proliferative effect. NUCC-0226272 has the potential for cancer research[1].
IC_{50} & Target	EZH2
In Vitro	NUCC-0226272 (0.01-10 μM; 5 days) shows anti-proliferative effect in LNCaP and 22Rv1 cells[1]. NUCC-0226272 (10 μM; 6 days) shows strong degradation of EZH2, as well as reduction of PRC2 component SUZ12, and reduced H3K27me3 levels in C4-2B cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pharmacokinetic Parameters of NUCC-0226272 in C57Bl/6 mouse[1].

	IP (4 mg/kg)
T_{max} (h)	0.83
C_{max} (ng/mL)	3650
AUC_{last} (min·ng/mL)	12777389
$t_{1/2}$ (h)	3.46
CL (mL/min/kg)	3.11
V_{ss} (L/kg)	3.11

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Gary E. Schiltz, et al. Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (ezh2) and proteolysis-targeting chimeric derivatives thereof (protacs) that induce degradation of ezh2. US20230346953A1.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA